BGB-B3227
- Generic Name
- BGB-B3227
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced CancerMetastatic Solid TumorAdvanced Solid TumorMetastatic Cancer
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 75
- Registration Number
- NCT06540066
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Washington University in St Louis, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath